Trexquant Investment LP Makes New $770,000 Investment in Liquidia Co. (NASDAQ:LQDA)

Trexquant Investment LP bought a new stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 64,040 shares of the company's stock, valued at approximately $770,000. Trexquant Investment LP owned 0.10% of Liquidia at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Fortitude Family Office LLC bought a new stake in shares of Liquidia in the 4th quarter valued at about $26,000. SG Americas Securities LLC increased its stake in shares of Liquidia by 17.4% in the 4th quarter. SG Americas Securities LLC now owns 15,540 shares of the company's stock valued at $187,000 after acquiring an additional 2,298 shares during the last quarter. Corton Capital Inc. increased its stake in shares of Liquidia by 14.2% in the 3rd quarter. Corton Capital Inc. now owns 23,440 shares of the company's stock valued at $149,000 after acquiring an additional 2,921 shares during the last quarter. Sigma Planning Corp increased its stake in shares of Liquidia by 5.4% in the 3rd quarter. Sigma Planning Corp now owns 95,640 shares of the company's stock valued at $606,000 after acquiring an additional 4,885 shares during the last quarter. Finally, Bleakley Financial Group LLC increased its stake in shares of Liquidia by 45.6% in the 4th quarter. Bleakley Financial Group LLC now owns 31,193 shares of the company's stock valued at $375,000 after acquiring an additional 9,764 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Liquidia news, General Counsel Russell Schundler sold 2,060 shares of the company's stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $30,034.80. Following the completion of the transaction, the general counsel now owns 486,027 shares of the company's stock, valued at approximately $7,086,273.66. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Liquidia news, General Counsel Russell Schundler sold 2,060 shares of the company's stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $30,034.80. Following the completion of the transaction, the general counsel now owns 486,027 shares of the company's stock, valued at approximately $7,086,273.66. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jason Adair sold 4,657 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.81, for a total value of $73,627.17. Following the transaction, the insider now directly owns 108,640 shares of the company's stock, valued at approximately $1,717,598.40. The disclosure for this sale can be found here. Insiders sold a total of 70,453 shares of company stock valued at $1,092,707 in the last quarter. 31.60% of the stock is currently owned by insiders.

Liquidia Stock Performance

NASDAQ LQDA traded up $0.01 during trading hours on Friday, reaching $12.87. 1,232,585 shares of the company's stock were exchanged, compared to its average volume of 888,966. The company's 50-day moving average is $13.51 and its two-hundred day moving average is $12.34. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99. The company has a market capitalization of $983.01 million, a price-to-earnings ratio of -8.25 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. The business had revenue of $4.53 million for the quarter, compared to the consensus estimate of $5.29 million. Research analysts predict that Liquidia Co. will post -1.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of Liquidia in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price target on shares of Liquidia in a research note on Wednesday, May 15th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $21.00.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).